StemCell Therapy

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the "Board" or "Directors"), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company’s Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.

Read the original post:
OKYO Pharma Limited – PDMR dealing

-- 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization -- 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization

Original post:
Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products...

TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

See the original post:
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the...

COPENHAGEN, Denmark, November 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

See original here:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

Company Files First 510(k) Application in Wound Care Company Files First 510(k) Application in Wound Care

Link:
Kane Biotech Announces Third Quarter 2022 Financial Results

People don't mate randomly but the flawed assumption that they do is an essential part of many studies linking genes to diseases and traits  The Conversation Indonesia

Read the original:
People don't mate randomly but the flawed assumption that they do is an essential part of many studies linking genes to diseases and traits - The...

Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry?  InvestorsObserver

See original here:
Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -59.36% This Week?  InvestorsObserver

Here is the original post:
Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -59.36% This Week? - InvestorsObserver

Should Biotechnology Stock LogicBio Therapeutics Inc (LOGC) Be in Your Portfolio Tuesday?  InvestorsObserver

Read more:
Should Biotechnology Stock LogicBio Therapeutics Inc (LOGC) Be in Your Portfolio Tuesday? - InvestorsObserver

PDS BIOTECHNOLOGY CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)  Marketscreener.com

See the rest here:
PDS BIOTECHNOLOGY CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.com

Biotechnology Industrial Training Program Winter Edition By Startup Incubation and Innovation Centre IIT Kanpur  BioTecNika

More here:
Biotechnology Industrial Training Program Winter Edition By Startup Incubation and Innovation Centre IIT Kanpur - BioTecNika

Where Does Axsome Therapeutics Inc (AXSM) Stock Fall in the Biotechnology Field After It Is Lower By -1.80% This Week?  InvestorsObserver

Original post:
Where Does Axsome Therapeutics Inc (AXSM) Stock Fall in the Biotechnology Field After It Is Lower By -1.80% This Week? - InvestorsObserver

Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?  Marketscreener.com

Read more here:
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval? - Marketscreener.com

BIOADAPTIVES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)  Marketscreener.com

See the article here:
BIOADAPTIVES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

Published in Journal for Immunotherapy of Cancer: Using Single-Cell Analysis to Assess the Effects of an Anti-OX40 Monoclonal Antibody in Its First-in-Human Phase I/II Study for Advanced Solid Cancer  Marketscreener.com

See more here:
Published in Journal for Immunotherapy of Cancer: Using Single-Cell Analysis to Assess the Effects of an Anti-OX40 Monoclonal Antibody in Its...

Man who had COVID-19 for 400 days finally cured after getting treated with antibodies, study says  msnNOW

Read the rest here:
Man who had COVID-19 for 400 days finally cured after getting treated with antibodies, study says - msnNOW

INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)  Marketscreener.com

See the original post here:
INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during forecast period of 2022-31 Future Market Insights, Inc.  GlobeNewswire

See the original post here:
3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during...

YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)  Marketscreener.com

See original here:
YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com

ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q)  Marketscreener.com

View original post here:
ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com